Welcoming low testosterone as a cardiovascular risk factor

被引：0
作者：
M Maggio
S Basaria
机构：
[1] University of Parma,Department of Internal Medicine, Division of Endocrinology & Metabolism
[2] Boston University School of Medicine,Department of Internal Medicine, Division of Endocrinology & Metabolism
来源：
International Journal of Impotence Research | 2009年 / 21卷
关键词：
hypogonadism; metabolic syndrome; diabetes; inflammation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Male hypogonadism now has a new spectrum of complications. They are mainly cardiometabolic in nature. Low serum testosterone levels are a risk factor for diabetes, metabolic syndrome, inflammation and dyslipidemia. These metabolic and inflammatory complications are not without consequences. Recent studies have shown low serum testosterone levels to be an independent risk factor of cardiovascular and all-cause mortality. It is time to welcome low serum testosterone levels as a cardiovascular risk factor.
引用
收藏
页码：261 / 264
页数：3
相关论文
共 159 条
  • [1] Basaria S(2001)Hypogonadism and androgen replacement therapy in elderly men Am J Med 110 563-572
  • [2] Dobs AS(2000)Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study Diabetes Care 23 490-494
  • [3] Stellato RK(2007)Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III) Diabetes Care 30 234-238
  • [4] Feldman HA(2004)Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men Diabetes Care 27 1036-1041
  • [5] Hamdy O(1992)The effects of testosterone treatment on body composition and metabolism in middle-aged obese men Int J Obes Relat Metab Disord 16 991-997
  • [6] Horton ES(2003)Testosteone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency Aging Male 6 1-7
  • [7] McKinlay JB(1996)Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues J Clin Endocrinol Metab 81 1018-1022
  • [8] Selvin E(2006) in men: effects of testosterone Cancer 106 581-588
  • [9] Feinleib M(2006)Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy J Clin Oncol 24 3979-3983
  • [10] Zhang L(2007)Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy Arch Intern Med 167 612-613
12345678910